Biotech Showcase is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Camille Samuels
Partner at Venrock

Profile

Camille Samuels is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family. She serves on the board of directors of Unity biotech (UBX), a public longevity company — and is an observer on the board at Corvidia, a private cardiorenal company.  Camille Samuels is a Partner at Venrock, a venture capital firm originally established in the late 1960s as the venture arm of the Rockefeller family.  She serves on the board of directors of Unity biotech (UBX), a public longevity company — and is an observer on the board at Corvidia, a private cardiorenal company.
Prior to Venrock, Cami spent over a decade as a Managing Director at Versant Ventures, a leading life sciences venture capital firm.  While at Versant, Cami seeded Kythera (makers of Kybella) and served on the company’s board through its IPO and eventual sale to Allergan for $2.1 B.  In addition, she served as a board member or a board observer on many other innovative healthcare companies including Achaogen (AKAO), Carmenta (acq. by Progenity), Fluidigm (FLDM), Genomic Health (GHDX), Novacardia (acquired by Merck), ParAllele (acq. by Affymetrix), and Syrrx (acq. by Takeda).

Camille Samuels's Network